Search

Juno joint venture seeks IPO haul to bring CAR-Ts to China - FierceBiotech

JW Therapeutics has filed the paperwork (PDF) for a Hong Kong IPO. The Juno Therapeutics-WuXi AppTech joint venture is seeking money to advance a cell therapy pipeline led by anti-CD19 CAR-T JWCAR029.

In 2016, Juno and WuXi teamed up to found JW. The biotech went on to raise $190 million over the course of its series A and B rounds, giving it the financial firepower to take JWCAR029 to a filing for approval in third-line diffuse large B-cell lymphoma in China while exploring the effect of the anti-CD19 CAR-T and other cell therapies on a range of different hematological and solid cancers. 

Now, with the commercial launch of JWCAR029 in sight, JW has filed to raise money in a Hong Kong IPO. The financing target is redacted from the paperwork, but earlier media reports suggest JW plans to raise $200 million to $300 million.

Whitepaper

Humanized Mouse Models for Drug Discovery: The NOG Portfolio

Human immune system mouse models are leading to breakthroughs in a wide range of research applications. In this white paper, explore the NOG portfolio and the unique benefits of each model to determine the appropriate choice for your study.

JW is seeking the money to continue developing JWCAR029, which is in development in five blood cancers, and build out an in-house sales and marketing team to support the launch of the CAR-T in China. The rest of the money will support development of JWCAR129, an anti-BCMA therapy that is in IND-enabling studies, and a solid tumor pipeline led by anti-AFP cell therapy JWATM203.

JWATM203 is yet to enter the clinic, but JW’s partner, Eureka Therapeutics, has taken its AFP T-cell therapy into phase 1/2 in the U.S. JW and Eureka are developing the AFP cell therapies as treatments for liver cancer. 

JW has another anti-AFP asset, JWATM213, in development that uses technology accessed through a collaboration with Lyell to enhance T-cell function and improve efficacy. Lyell and JW disclosed their solid tumor collaboration, which also includes an anti-GPC3 program, last week. The IPO paperwork fleshes out the details, revealing Lyell has granted JW a license to T-cell anti-exhaustion functionality.

The partnership brings together biotechs with strong links to Juno. Lyell’s founder and CEO is Rick Klausner, the co-founder of Juno. JW was set up by pioneering Seattle-based CAR-T biotech Juno.  

Let's block ads! (Why?)



"bring" - Google News
August 17, 2020 at 07:40PM
https://ift.tt/2PWKBks

Juno joint venture seeks IPO haul to bring CAR-Ts to China - FierceBiotech
"bring" - Google News
https://ift.tt/38Bquje
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update

Bagikan Berita Ini

0 Response to "Juno joint venture seeks IPO haul to bring CAR-Ts to China - FierceBiotech"

Post a Comment

Powered by Blogger.